Mariam Amghar, MS

Mariam Amghar is a PhD candidate in Clinical Oncology at Heidelberg University and the German Cancer Research Center (DKFZ), specializing in translational genomics, real-world data analytics, and AI-driven biomarker discovery. Her current research focuses on developing circulating tumor DNA (ctDNA) biomarkers to predict clinical outcomes and treatment response in metastatic castration-resistant prostate cancer (mCRPC) patients undergoing radioligand therapy. By integrating genomic data with clinical and preclinical models, Mariam aims to optimize personalized treatment strategies and improve patient selection. She holds a Master’s degree in Pharmaceutical Biotechnology from the University of Padua, graduating with highest honors (110/110 Cum Laude), and a Bachelor’s degree in Pharmaceutical-Medical Biotechnology from the University of Florence. Her academic journey also includes a study abroad period at the University of Bern through the Swiss Erasmus Mobility Program. Mariam has collaborated with leading institutions including Bayer AG and the European Molecular Biology Laboratory (EMBL), applying bioinformatics and molecular biology approaches to enhance radiopharmaceutical therapy development. She is skilled in programming languages such as Python and R, and experienced in analyzing large-scale genomic and clinical datasets. Beyond research, Mariam leads the communication team for DKFZ’s R&D Career Day and mentors new PhD students, demonstrating strong leadership and project management skills. She has presented her work at prominent international conferences including ASTRO and EANM, earning recognition for her contributions to prostate cancer biomarker research.

Disclosures:

• Employment: none
• Compensation: none
• Ownership: none
• Leadership: none